19,456 Merck & Co., Inc. $MRK Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC trimmed its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 3.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 532,699 shares of the company's stock after selling 19,456 shares during the period. Douglas Lane & Associates LLC's holdings in Merck & Co., Inc. were worth $77,406,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of MRK. Susquehanna Fundamental Investments LLC bought a new position in shares of Merck & Co., Inc. in the 2nd quarter worth $11,470,000. Russell Investments Group Ltd. grew its position in Merck & Co., Inc. by 2.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company's stock worth $331,931,000 after acquiring an additional 51,393 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Merck & Co., Inc. by 7.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company's stock worth $794,577,000 after purchasing an additional 402,011 shares during the last quarter. Talon Private Wealth LLC purchased a new position in Merck & Co., Inc. during the 2nd quarter valued at $995,000. Finally, Panagora Asset Management Inc. lifted its stake in shares of Merck & Co., Inc. by 410.5% in the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company's stock valued at $74,255,000 after purchasing an additional 567,249 shares during the period. Hedge funds and other institutional investors own 76.07% of the company's stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with PD-1/PD-L1 therapy. The decision expands Merck’s commercial oncology portfolio and could provide an additional growth opportunity alongside Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, adding a potentially valuable pipeline program. Merck Wins FDA Approval for WELIREG Plus LENVIMA
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while maintaining a neutral rating. The higher target reflects improved valuation support, although it implies limited upside at recent trading levels. Cantor Fitzgerald Raises Pharma Price Targets
• Neutral Sentiment: Analyst views remain divided: Morgan Stanley issued a buy rating in one report, while a separate report highlighted a pessimistic forecast. The conflicting outlooks suggest that Merck’s current valuation and future growth profile remain debated. Morgan Stanley Gives Merck a Buy Rating
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, but the relatively small holding is unlikely to materially affect the company’s fundamentals. Apella Capital Increases Merck Stake
• Negative Sentiment: A Dutch court blocked Merck’s subcutaneous Keytruda from being sold in eight European markets after Halozyme won an injunction in a patent dispute. The ruling could delay or restrict a potentially important, more convenient Keytruda formulation and increase litigation risk. Halozyme Wins Court Order Blocking Keytruda SC in Europe
• Negative Sentiment: Industry analysts identify Merck as one of the pharmaceutical companies most exposed to near-term generic competition as major patents expire. That patent-cliff risk could pressure revenue and earnings growth beyond the current period. Pharma Patent Cliff Risks

Merck & Co., Inc. Stock Up 2.5%

Shares of MRK traded up $3.49 during trading hours on Friday, hitting $145.87. The company had a trading volume of 3,216,070 shares, compared to its average volume of 10,622,946. The company has a market capitalization of $359.89 billion, a PE ratio of 116.63, a price-to-earnings-growth ratio of 6.42 and a beta of 0.21. The company's fifty day moving average price is $143.59 and its two-hundred day moving average price is $128.16. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the firm earned $2.13 earnings per share. Merck & Co., Inc.'s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.67 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.'s dividend payout ratio is currently 272.00%.

Insider Buying and Selling

In other news, EVP Chirfi Guindo sold 10,000 shares of the company's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the sale, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. This represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Maraldo sold 18,706 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president owned 18,212 shares of the company's stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock valued at $29,977,783 in the last 90 days. 0.17% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MRK. Wolfe Research boosted their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 25th. Leerink Partners increased their price target on Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 9th. Wall Street Zen downgraded shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. Rothschild & Co Redburn boosted their target price on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, July 6th. Finally, Sanford C. Bernstein lifted their price objective on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a "market perform" rating in a research note on Tuesday, August 4th. Seventeen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $151.32.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.